A Double-blinded Placebo-controlled Multiple Dose Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects With Prediabetes and With Overweight or Obesity
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs NN 9030 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 19 Jul 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 26 Apr 2017 Status changed from recruiting to active, no longer recruiting.